Skip to main content

Table 1 Mechanism of action and species specificity of translation inhibitors

From: The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials

Compound

Specificity

Mechanism of action

References

Bruceantin

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits initiation

[16, 17]  

Verrucarin A

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits initiation, binds between P- & A- sites

[13,14,15]  

Suramin

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits initation & elongation, multiple binding sites

[18]  

Anisomycin

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits elongation, binds A-site

[13, 17]

Cycloheximide

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits elongation, binds E-site

[13]

Homoharringtonine

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits elongation on re-initiating ribosomes, binds A-site

[13, 20]

Lactimidomycin

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits elongation, binds E-site

[13]

Nagilactone C

Eukaryotic (Pf cytoplasmic ribosomes)

Inhibits elongation, binds A-site

[13, 21]

Puromycin

Pan-inhibitor

tRNA mimetic

[23, 24]

Halofuginone

Eukaryotic

Inhibits glutamyl-prolyl-tRNA synthetase

[22]

Thiostrepton

Prokaryotic (Pf mitochondrial & apicoplast ribosomes)

Inhibits initiation & elongation

[25,26,27,28,29,30,– 31]